Stifel Financial Corp Sells 6,316 Shares of Amgen Inc. (NASDAQ:AMGN)

Stifel Financial Corp lessened its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,402,444 shares of the medical research company's stock after selling 6,316 shares during the quarter. Stifel Financial Corp owned about 0.26% of Amgen worth $365,564,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the stock. Capital World Investors boosted its stake in Amgen by 1,292.0% in the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock worth $1,693,042,000 after purchasing an additional 6,029,058 shares during the period. Norges Bank bought a new stake in shares of Amgen in the fourth quarter valued at about $1,541,991,000. Capital International Investors boosted its position in shares of Amgen by 40.1% during the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after buying an additional 3,495,503 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Amgen by 25.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after buying an additional 2,672,975 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Amgen in the 4th quarter valued at approximately $401,913,000. Institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Truist Financial lowered their price objective on shares of Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a report on Wednesday, January 8th. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Royal Bank of Canada reissued an "outperform" rating and set a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research report on Thursday, April 17th. Finally, Piper Sandler Companies reissued an "overweight" rating and issued a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $310.57.

Amgen Stock Up 0.7 %

Shares of AMGN traded up $1.94 during trading hours on Thursday, reaching $279.84. The stock had a trading volume of 2,259,859 shares, compared to its average volume of 2,789,386. The company has a market capitalization of $150.46 billion, a price-to-earnings ratio of 37.06, a P/E/G ratio of 2.63 and a beta of 0.59. The firm has a 50-day simple moving average of $301.98 and a 200 day simple moving average of $293.34. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.40%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David M. Reese sold 25,225 shares of the firm's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. Corporate insiders own 0.69% of the company's stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.